| Stereochemistry | ACHIRAL |
| Molecular Formula | C18H16N2O3 |
| Molecular Weight | 308.3312 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN1C=C(C(O)=O)C(=O)C2=C1N=C(CC3=CC=CC=C3)C=C2
InChI
InChIKey=WHHHJDGNBVQNAU-UHFFFAOYSA-N
InChI=1S/C18H16N2O3/c1-2-20-11-15(18(22)23)16(21)14-9-8-13(19-17(14)20)10-12-6-4-3-5-7-12/h3-9,11H,2,10H2,1H3,(H,22,23)
| Molecular Formula | C18H16N2O3 |
| Molecular Weight | 308.3312 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
PubMed
Patents
Sample Use Guides
adult rats: Amfonelic acid (AFA) was administered (20 mg/kg, i.p.) at the same time the last methamphetamine (MA) dose was given. AFA treatment completely prevented the effects of MA on the dopaminergic system, both morphologically and biochemically
Route of Administration:
Intraperitoneal
